Skip to content

Comparison of the effectiveness of two treatment regimens in patients with COVID-19

Comparison of the effectiveness of Sovodak (sofosbuvir + Daklatasvir) and Keltra treatment regimens in patients with COVID-19: a randomized single-blind study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200328046885N1
Enrollment
300
Registered
2020-10-12
Start date
2020-07-19
Completion date
Unknown
Last updated
2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. COVID-19

Interventions

Intervention 1: Intervention group: out of 300 patients, 150 patients with coronary artery from two medical centers (Rasoul Akram Hospital and Firoozgar Hospital) hydroxychloroquine phosphate treatmen

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Definitive diagnosis of Covid-19 Inpatients Age older than or equal to 18 years

Exclusion criteria

Exclusion criteria: Pregnant women Breastfeeding women People with decreased level of consciousness Blood pressure less than 60/90 mm Hg Respiratory rate above 24 hypoxia Reduction of saturation less than 90% Patients with various organ failure Patients required mechanical ventilation at the time of admission

Design outcomes

Primary

MeasureTime frame
Death. Timepoint: 14,3,2,1,0 days after the start of the intervention. Method of measurement: The ratio of death to total patients in each group.;Recovery and discharge from the hospital. Timepoint: End of treatment. Method of measurement: Examine the patient and perform tests.

Secondary

MeasureTime frame
Duration of hospitalization. Timepoint: End of study. Method of measurement: File information.;Need to be admitted to the ICU (Intensive care units). Timepoint: After the intervention. Method of measurement: See the patient's clinical signs and tests.;Requires four drug treatments. Timepoint: During treatment. Method of measurement: Patient examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahin Jamshidi Makiani

Iran University of Medical Sciences

Jamshidimakiani.m@iums.ac.ir+98 21 8893 7383

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 14, 2026